Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epstein‐Barr virus post‐transplant lymphoproliferative disease ( PTLD ) after hematopoietic stem cell transplantation

27 Jun 2018

Abstract excerpt

Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29949208
DOI: 10.1111/ejh.13131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epstein‐Barr virus post‐transplant lymphoproliferative disease ( PTLD ) after hematopoietic stem cell transplantationPMID 29949208Read ↗

Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatmentSemantic proximity Read ↗

Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.Semantic proximity Read ↗

Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamideSemantic proximity Read ↗

Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated DisordersSemantic proximity Read ↗

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative DiseaseSemantic proximity Read ↗

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.Semantic proximity Read ↗

Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantationSemantic proximity Read ↗

"Unusual" viral diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, retrospective studySemantic proximity Read ↗

Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.Semantic proximity Read ↗

Epstein–Barr virus-positive T/NK-cell lymphoproliferative disordersSemantic proximity Read ↗

Posttransplant Lymphoproliferative DisordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.